Gentler myeloma combo aims to help frail patients fight relapse
NCT ID NCT05911321
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests a three-drug combination (isatuximab, pomalidomide, and dexamethasone) at lower-than-standard doses in people with multiple myeloma that has returned or not responded to treatment. The goal is to see if the lower doses are both safe and effective for patients who are more vulnerable to side effects due to age or other health problems. About 6 participants will receive the treatment, and researchers will measure how many achieve a meaningful reduction in cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.